Ramon E Parsons

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5581230/publications.pdf

Version: 2024-02-01

129 papers	39,704 citations	23879 60 h-index	17373 126 g-index
132 all docs	132 docs citations	132 times ranked	33547 citing authors

#	Article	IF	Citations
1	Machine Learning Approaches for Early Prostate Cancer Prediction Based on Healthcare Utilization Patterns. Studies in Health Technology and Informatics, 2022, 289, 65-68.	0.2	1
2	Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structureâ€“Activity Relationship Studies. Journal of Medicinal Chemistry, 2022, 65, 3644-3666.	2.9	20
3	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. Frontiers in Medicine, 2022, 9, 849222.	1.2	2
4	Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. Cell Reports, 2022, 39, 110637.	2.9	12
5	Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma. Molecular Cancer Research, 2022, 20, 1193-1207.	1.5	7
6	Abstract IA012: Recent progress with PTEN. , 2021, , .		0
7	NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Communications Biology, 2021, 4, 312.	2.0	16
8	AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathwayâ€“Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discovery, 2021, 11, 3064-3089.	7.7	32
9	Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders. Journal of Medicinal Chemistry, 2021, 64, 18054-18081.	2.9	27
10	Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology, 2020, 16, 214-222.	3.9	148
11	Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 718-723.	2.0	6
12	Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma. Gastroenterology, 2020, 159, 2203-2220.e14.	0.6	47
13	Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036129.	2.9	30
14	PIK3CA and p53 Mutations Promote 4NQO-Initated Head and Neck Tumor Progression and Metastasis in Mice. Molecular Cancer Research, 2020, 18, 822-834.	1.5	10
15	Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of ex vivo Expanded Human Hematopoietic Stem Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 592348.	1.8	8
16	Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene, 2019, 38, 47-59.	2.6	20
17	PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription. Nucleic Acids Research, 2019, 47, 5573-5586.	6.5	24
18	Restoring tumor suppression. Science, 2019, 364, 633-634.	6.0	4

#	Article	IF	Citations
19	Ten Essential Practices for Developing or Reforming a Biostatistics Core for a NCI Designated Cancer Center. JNCI Cancer Spectrum, 2018, 2, pky010.	1.4	5
20	PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discovery, 2017, 7, 380-390.	7.7	94
21	p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. Molecular Cancer Research, 2017, 15, 1051-1062.	1.5	51
22	Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Translational Oncology, 2017, 10, 357-366.	1.7	31
23	Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity. Immunity, 2017, 47, 1169-1181.e7.	6.6	45
24	Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. Cell Reports, 2016, 16, 472-486.	2.9	95
25	Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer, 2016, 16, 587.	1.1	26
26	PREX1 Protein Function Is Negatively Regulated Downstream of Receptor Tyrosine Kinase Activation by p21-activated Kinases (PAKs). Journal of Biological Chemistry, 2016, 291, 20042-20054.	1.6	20
27	Molecular Pathways: Targeting the PI3K Pathway in Cancerâ€"BET Inhibitors to the Rescue. Clinical Cancer Research, 2016, 22, 2605-2610.	3.2	37
28	PTEN and NEDD4 in Human Breast Carcinoma. Pathology and Oncology Research, 2016, 22, 41-47.	0.9	19
29	Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell, 2015, 27, 837-851.	7.7	205
30	A new class of cancer-associated PTEN mutations defined by membrane translocation defects. Oncogene, 2015, 34, 3737-3743.	2.6	32
31	PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. Science Signaling, 2015, 8, ra32.	1.6	53
32	Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human Î²-Cells. Diabetes, 2015, 64, 3784-3797.	0.3	52
33	p21-activated Kinases (PAKs) Mediate the Phosphorylation of PREX2 Protein to Initiate Feedback Inhibition of Rac1 GTPase. Journal of Biological Chemistry, 2015, 290, 28915-28931.	1.6	14
34	Analysis of intracellular PTEN signaling and secretion. Methods, 2015, 77-78, 164-171.	1.9	11
35	New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond. Discoveries, 2014, 2, e15.	1.5	32
36	Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 155-160.	3.3	61

#	Article	IF	Citations
37	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. Science Signaling, 2014, 7, pe15.	1.6	50
38	Molecular Pathways: Intercellular PTEN and the Potential of PTEN Restoration Therapy. Clinical Cancer Research, 2014, 20, 5379-5383.	3.2	40
39	PTEN function: the long and the short of it. Trends in Biochemical Sciences, 2014, 39, 183-190.	3.7	231
40	Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget, 2014, 5, 10503-10517.	0.8	44
41	Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biology and Therapy, 2013, 14, 246-253.	1.5	29
42	RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation. Cell Research, 2013, 23, 552-564.	5.7	65
43	A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival. Science, 2013, 341, 399-402.	6.0	270
44	Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clinical Cancer Research, 2013, 19, 6830-6841.	3.2	60
45	Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. Genes and Development, 2013, 27, 916-927.	2.7	42
46	PREX2, a new breed of cancer gene with too many spots?. Pigment Cell and Melanoma Research, 2012, 25, 409-410.	1.5	1
47	Abnormal elevated PTEN expression in the mouse antrum of a model of GIST KitK641E/K641E. Cellular Signalling, 2011, 23, 1857-1868.	1.7	4
48	mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinaseâ€“Driven Feedback Loop. Cancer Discovery, 2011, 1, 203-204.	7.7	10
49	Defining Variations in Survival of BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2011, 306, 1597.	3.8	2
50	Reduction ofPtendose leads to neoplastic development in multiple organs ofPten^{shRNA}mice. Cancer Biology and Therapy, 2010, 10, 1194-1200.	1.5	31
51	Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer. Molecular Cell, 2010, 40, 877-892.	4.5	194
52	3-Phosphoinositideâ€“Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma. Cancer Research, 2009, 69, 6299-6306.	0.4	126
53	Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle, 2009, 8, 2198-2210.	1.3	107
54	Activation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a. Science, 2009, 325, 1261-1265.	6.0	228

#	Article	IF	Citations
55	PTEN Loss Promotes Mitochondrially Dependent Type II Fas-Induced Apoptosis via PEA-15. Molecular and Cellular Biology, 2009, 29, 1222-1234.	1.1	41
56	Irs2 Inactivation Suppresses Tumor Progression in Pten+/â˜’ Mice. American Journal of Pathology, 2009, 174, 276-286.	1.9	22
57	Gab2-Mediated Signaling Promotes Melanoma Metastasis. American Journal of Pathology, 2009, 174, 1524-1533.	1.9	67
58	PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene, 2008, 27, 4657-4665.	2.6	131
59	The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene, 2008, 27, 5477-5485.	2.6	338
60	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics, 2008, 40, 102-107.	9.4	316
61	Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14076-14081.	3.3	210
62	The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration. Cancer Research, 2008, 68, 1862-1871.	0.4	149
63	BAF180 Is a Critical Regulator of p21 Induction and a Tumor Suppressor Mutated in Breast Cancer. Cancer Research, 2008, 68, 1667-1674.	0.4	143
64	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16224-16229.	3.3	285
65	Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro-Oncology, 2007, 9, 271-279.	0.6	144
66	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7564-7569.	3.3	445
67	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine, 2007, 13, 1203-1210.	15.2	804
68	Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia, 2007, 50, 395-403.	2.9	71
69	Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. Journal of Neuro-Oncology, 2007, 85, 11-24.	1.4	25
70	Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL.. Blood, 2007, 110, 5-5.	0.6	2
71	Analysis of PTEN Mutation in Non-familial Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 317-331.	1.8	5
72	Physiological levels of PTEN control the size of the cellular Ins(1,3,4,5,6)P5 pool. Cellular Signalling, 2006, 18, 488-498.	1.7	11

#	Article	IF	Citations
73	The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. Oncogene, 2005, 24, 2735-2738.	2.6	16
74	Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell, 2005, 7, 193-204.	7.7	305
75	Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/â^' Mice. Current Biology, 2005, 15, 1839-1846.	1.8	141
76	Two somatic biallelic lesions within and nearSMAD4 in a human breast cancer cell line. Genes Chromosomes and Cancer, 2005, 42, 372-383.	1.5	11
77	PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma. Cancer Research, 2005, 65, 2554-2559.	0.4	813
78	PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes and Development, 2005, 19, 1662-1667.	2.7	214
79	Phosphatase and Tensin Homolog Regulation of Islet Growth and Glucose Homeostasis. Journal of Biological Chemistry, 2005, 280, 39388-39393.	1.6	44
80	Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer: Fig. 1.. Clinical Cancer Research, 2005, 11, 7965-7966.	3.2	10
81	HIN-1, an Inhibitor of Cell Growth, Invasion, and AKT Activation. Cancer Research, 2005, 65, 9659-9669.	0.4	61
82	PTEN Loss Inhibits CHK1 to Cause Double Stranded-DNA Breaks in Cells. Cell Cycle, 2005, 4, 927-929.	1.3	95
83	The Oncogenetic Basis of Breast Cancer. , 2005, , 15-26.		0
84	Is the small heat shock protein ÂB-crystallin an oncogene?. Journal of Clinical Investigation, 2005, 116, 30-32.	3.9	43
85	Distinct IL-2 Receptor Signaling Pattern in CD4+CD25+ Regulatory T Cells. Journal of Immunology, 2004, 172, 5287-5296.	0.4	241
86	The New York Cancer Project: Rationale, Organization, Design, and Baseline Characteristics. Journal of Urban Health, 2004, 81, 301-310.	1.8	83
87	Human cancer, PTEN and the PI-3 kinase pathway. Seminars in Cell and Developmental Biology, 2004, 15, 171-176.	2.3	197
88	PTEN: from pathology to biology. Trends in Cell Biology, 2003, 13, 478-483.	3.6	314
89	PTEN and Cancer. , 2003, 222, 147-166.		55
90	HLTF gene silencing in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4562-4567.	3.3	145

#	Article	IF	Citations
91	Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1455-1460.	3.3	134
92	Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2884-2889.	3.3	295
93	DNA Mismatch Repair Deficiency Accelerates Endometrial Tumorigenesis in Pten Heterozygous Mice. American Journal of Pathology, 2002, 160, 1481-1486.	1.9	65
94	Reduced expression of PTEN correlates with breast cancer progression. Human Pathology, 2002, 33, 405-409.	1.1	123
95	PTEN: Life as a Tumor Suppressor. Experimental Cell Research, 2001, 264, 29-41.	1.2	606
96	Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Molecular Biology, 2001, 2, 2.	3.0	78
97	An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10320-10325.	3.3	582
98	Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11563-11568.	3.3	291
99	PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2. Molecular and Cellular Biology, 2001, 21, 3947-3958.	1.1	59
100	1Oq23.3 loss of heterozygosity is higher inlymph node-positive (PT2-3,N+) versus lymph node-negative (PT2-3,N0) prostate cancer. Human Pathology, 2000, 31, 504-508.	1.1	51
101	Differential subtraction chain, a method for identifying differences in genomic DNA and mRNA. Nucleic Acids Research, 1999, 27, 24e-24.	6.5	27
102	Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1563-1568.	3.3	912
103	Analysis ofPTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes and Cancer, 1999, 24, 322-327.	1.5	46
104	PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 1998, 16, 2259-2264.	2.6	300
105	Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 1998, 16, 3215-3218.	2.6	175
106	Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene, 1998, 17, 123-127.	2.6	99
107	Mutational analysis of thePTEN gene in head and neck squamous cell carcinoma. , 1998, 77, 684-688.		77
108	Analysis of the PTEN gene in human meningiomas. Neuropathology and Applied Neurobiology, 1998, 24, 3-8.	1.8	55

#	Article	IF	Citations
109	Inhibition of Cell Migration, Spreading, and Focal Adhesions by Tumor Suppressor PTEN. Science, 1998, 280, 1614-1617.	6.0	1,113
110	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Human Molecular Genetics, 1998, 7, 507-515.	1.4	578
111	Phosphatases and tumorigenesis. Current Opinion in Oncology, 1998, 10, 88.	1.1	60
112	P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9052-9057.	3.3	765
113	PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. Science, 1997, 275, 1943-1947.	6.0	4,506
114	Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics, 1997, 16, 64-67.	9.4	1,902
115	Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genetics, 1997, 16, 333-334.	9.4	622
116	Molecular genetics and hereditary cancer. Cancer, 1997, 80, 533-536.	2.0	1
117	Pathology and genetic testing. Cancer, 1997, 80, 636-648.	2.0	2
118	Analysis of mismatch repair genes in hereditary nonâ€“polyposis colorectal cancer patients. Nature Medicine, 1996, 2, 169-174.	15.2	892
119	Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genetics, 1995, 9, 48-55.	9.4	759
120	Genetic instability occurs in the majority of young patients with colorectal cancer. Nature Medicine, 1995, 1, 348-352.	15.2	355
121	Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science, 1995, 268, 1336-1338.	6.0	2,173
122	Mutations of GTBP in genetically unstable cells. Science, 1995, 268, 1915-1917.	6.0	476
123	Mismatch repair deficiency in phenotypically normal human cells. Science, 1995, 268, 738-740.	6.0	304
124	The Molecular Basis of Turcot's Syndrome. New England Journal of Medicine, 1995, 332, 839-847.	13.9	1,060
125	WAF1, a potential mediator of p53 tumor suppression. Cell, 1993, 75, 817-825.	13.5	8,091
126	Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 1993, 75, 1215-1225.	13.5	2,195

#	Article	IF	Citations
127	Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell, 1993, 75, 1227-1236.	13.5	1,031
128	The side-chain cleavage of cholesterol sulfateâ€”III. the effect of adrenodoxin, membrane phospholipids and tween 80 on the kinetics of oxidation of the sterol sulfate by a reconstituted cholesterol desmolase system. The Journal of Steroid Biochemistry, 1986, 24, 909-916.	1.3	5
129	The side-chain cleavage of cholesterol sulfateâ€”II. The effect of phospholipids on the oxidation of the sterol sulfate by inner mitochondrial membranes and by a reconstituted cholesterol desmolase system. The Journal of Steroid Biochemistry, 1985, 23, 313-321.	1.3	10